Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Docetaxel therapy is approved for castration-resistant metastatic prostate cancer. However, it is unknown whether docetaxel should be added to the treatment regimen after patients become resistant to androgen deprivation therapy or only once they develop metastasis. Therefore, the aim of the study was to identify demographic, clinical and genetic predictors of docetaxel response which would help optimize both its use and timing for initiation.
Presenter: Paolo Tarantino
Session: Poster Display & Cocktail
Resources:
Abstract
Presenter: Madhumathi Jayaprakasam
Session: Poster Display & Cocktail
Resources:
Abstract
Presenter: Guillermo Prado
Session: Poster Display & Cocktail
Resources:
Abstract
Presenter: Ali Jahanian-Najafabadi
Session: Poster Display & Cocktail
Resources:
Abstract
Presenter: Eric Angevin
Session: Poster Display & Cocktail
Resources:
Abstract
Presenter: Mohanad Nada
Session: Poster Display & Cocktail
Resources:
Abstract
Presenter: Rana Youness
Session: Poster Display & Cocktail
Resources:
Abstract
Presenter: Eduardo Castanon Alvarez
Session: Poster Display & Cocktail
Resources:
Abstract
Presenter: Gil Awada
Session: Poster Display & Cocktail
Resources:
Abstract
Presenter: Wael Jdey
Session: Poster Display & Cocktail
Resources:
Abstract
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
